K. Garrett Evensen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
K. Garrett Evensen has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Havas
Sanford Burnham Prebys Medical Discovery Institute, La Jolla, USA
2 shared publications - Adarsh Rajesh
Sanford Burnham Prebys Medical Discovery Institute, La Jolla CA
2 shared publications - Allen Wang
Center for Epigenomics, Department of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA
2 shared publications Andrew Davis
Cancer Genome and Epigenetics Program; Sanford Burnham Prebys MDI; La Jolla, CA, USA
2 shared publications- April E. Williams
Salk Institute for Biological Studies
2 shared publications - Guillermina Garcia
Shared Resources; NCI-designated Cancer Center; Sanford Burnham Prebys MDI; La Jolla, CA, USA
2 shared publications
Latest Publications
- Open Access
p53 supports healthy aging
P53 is a master regulator of cellular stress responses that is also implicated in the aging process. Its role in aging is often considered an example of antagonistic pleiotropy (AP), where it acts beneficially as a tumor suppressor early in life, but detrimentally in late life, for example by driving accumulation of stress-associated, pro-inflammatory senescent cells. However, the causal role of p53 in aging is not well-defined, and the AP model has not been definitively tested through loss- of-function studies. Here we show, contrary to the prediction of AP, that p53 promotes healthy aging in mouse liver by suppressing excessive inflammation and maintaining metabolic function. Multimodal RNA, protein, epigenetic and spatial profiling at the single-cell level in aged mouse liver confirmed age-dependent increase in p53 pathway activation. Hepatocyte-specific knockout of p53 in livers of aged mice, but not of young mice, increased inflammation and immune infiltration. Mechanistically, p53 suppressed DNA replication stress and DNA damage, known precursors to inflammatory signaling. In aged hepatocytes, p53 also directly targeted and maintained expression of metabolic genes, and knockout of p53 sensitized aged mice to metabolic stress-induced liver damage. Complementing these loss-of-function data, pharmacological activation of p53 with the small-molecule MDM2 inhibitor HDM201 in aged mice reversed age-associated suppression of metabolic genes, decreased age-associated inflammation and delayed onset of frailty. These results identify p53 activity in aged tissue as protective rather than degenerative. Importantly, this protective function is pharmacologically targetable, potentially for the benefit of healthy aging in humans.
Open Accessp53 supports healthy aging
P53 is a master regulator of cellular stress responses that is also implicated in the aging process. Its role in aging is often considered an example of antagonistic pleiotropy (AP), where it acts beneficially as a tumor suppressor early in life, but detrimentally in late life, for example by driving accumulation of stress-associated, pro-inflammatory senescent cells. However, the causal role of p53 in aging is not well-defined, and the AP model has not been definitively tested through loss- of-function studies. Here we show, contrary to the prediction of AP, that p53 promotes healthy aging in mouse liver by suppressing excessive inflammation and maintaining metabolic function. Multimodal RNA, protein, epigenetic and spatial profiling at the single-cell level in aged mouse liver confirmed age-dependent increase in p53 pathway activation. Hepatocyte-specific knockout of p53 in livers of aged mice, but not of young mice, increased inflammation and immune infiltration. Mechanistically, p53 suppressed DNA replication stress and DNA damage, known precursors to inflammatory signaling. In aged hepatocytes, p53 also directly targeted and maintained expression of metabolic genes, and knockout of p53 sensitized aged mice to metabolic stress-induced liver damage. Complementing these loss-of-function data, pharmacological activation of p53 with the small-molecule MDM2 inhibitor HDM201 in aged mice reversed age-associated suppression of metabolic genes, decreased age-associated inflammation and delayed onset of frailty. These results identify p53 activity in aged tissue as protective rather than degenerative. Importantly, this protective function is pharmacologically targetable, potentially for the benefit of healthy aging in humans.
- Open Access
Age-associated repression of HNF4α is a driver and potential therapeutic target in liver metabolic dysfunction
Aging is a major risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD). However, the mechanisms by which aging disrupts hepatocyte transcriptional networks to drive metabolic dysfunction remain poorly understood. Hepatocyte nuclear factor 4 alpha (HNF4α) is a master regulator of hepatocyte identity and metabolic homeostasis, but its role in liver aging has not been defined. Here, we perform a comprehensive multi-omic profiling of young and aged mouse livers combined with targeted HNF4α functional studies to define how aging remodels HNF4α-dependent gene regulation and whether HNF4α can be a target to reverse age-associated liver dysfunction. Despite preserved HNF4α expression with age, aging was associated with reduced HNF4α chromatin occupancy and transcriptional activity, accompanied by epigenetic remodeling, including changes in histone acetylation, chromatin accessibility, and DNA methylation. Integration and comparison of HNF4α CUT&RUN with hepatocyte-specific Hnf4a deletion in young and aged livers identified high-confidence overlapping but distinct young- and old-specific HNF4α target gene networks. In young hepatocytes, HNF4α coordinates two complementary transcriptional programs: activation of genes governing hepatocyte identity, lipid metabolism, and metabolic function, while simultaneously inhibiting alternative developmental, proliferative, and inflammatory programs. Spatial transcriptomic analyses further revealed zone-specific specialization of HNF4α-dependent gene programs. Aging selectively disrupted these regulatory networks, resulting in compromised liver identity and metabolic gene programs, de-repression of inflammatory pathways and alternative cellular identity programs and disrupted hepatocyte zonation, consistent with age-dependent lipidomic and metabolic changes, hepatic fat accumulation, and immune infiltration. Hepatocyte-specific Hnf4a deletion in young mice recapitulated key features of liver aging, including impaired hepatocyte identity, metabolic dysfunction, steatosis, inflammatory activation and altered hepatic immune-cell composition, while deletion in aged mice further exacerbated steatosis, inflammation, and hepatic dysfunction. Conversely, hepatocyte-specific HNF4α restoration in aged mice significantly reduced hepatic steatosis and lipid accumulation, restored fatty acid metabolic programs, and partially reversed age-associated transcriptional changes. However, inflammatory and interferon-associated programs were not uniformly reversed, revealing differential responsiveness of metabolic and inflammatory pathways to HNF4α restoration. Together, these findings identify age-associated impairment of HNF4α activity as a functional contributor to liver aging, linking dysregulation of hepatocyte identity, metabolic homeostasis, and inflammatory control to age-associated hepatic dysfunction. Importantly, the selective reversibility of metabolic defects following HNF4α restoration establishes HNF4α as a promising strategy for preserving hepatocyte homeostasis and reversing age-associated hepatic metabolic dysfunction.
Open AccessAge-associated repression of HNF4α is a driver and potential therapeutic target in liver metabolic dysfunction
Aging is a major risk factors for metabolic dysfunction-associated steatotic liver disease (MASLD). However, the mechanisms by which aging disrupts hepatocyte transcriptional networks to drive metabolic dysfunction remain poorly understood. Hepatocyte nuclear factor 4 alpha (HNF4α) is a master regulator of hepatocyte identity and metabolic homeostasis, but its role in liver aging has not been defined. Here, we perform a comprehensive multi-omic profiling of young and aged mouse livers combined with targeted HNF4α functional studies to define how aging remodels HNF4α-dependent gene regulation and whether HNF4α can be a target to reverse age-associated liver dysfunction. Despite preserved HNF4α expression with age, aging was associated with reduced HNF4α chromatin occupancy and transcriptional activity, accompanied by epigenetic remodeling, including changes in histone acetylation, chromatin accessibility, and DNA methylation. Integration and comparison of HNF4α CUT&RUN with hepatocyte-specific Hnf4a deletion in young and aged livers identified high-confidence overlapping but distinct young- and old-specific HNF4α target gene networks. In young hepatocytes, HNF4α coordinates two complementary transcriptional programs: activation of genes governing hepatocyte identity, lipid metabolism, and metabolic function, while simultaneously inhibiting alternative developmental, proliferative, and inflammatory programs. Spatial transcriptomic analyses further revealed zone-specific specialization of HNF4α-dependent gene programs. Aging selectively disrupted these regulatory networks, resulting in compromised liver identity and metabolic gene programs, de-repression of inflammatory pathways and alternative cellular identity programs and disrupted hepatocyte zonation, consistent with age-dependent lipidomic and metabolic changes, hepatic fat accumulation, and immune infiltration. Hepatocyte-specific Hnf4a deletion in young mice recapitulated key features of liver aging, including impaired hepatocyte identity, metabolic dysfunction, steatosis, inflammatory activation and altered hepatic immune-cell composition, while deletion in aged mice further exacerbated steatosis, inflammation, and hepatic dysfunction. Conversely, hepatocyte-specific HNF4α restoration in aged mice significantly reduced hepatic steatosis and lipid accumulation, restored fatty acid metabolic programs, and partially reversed age-associated transcriptional changes. However, inflammatory and interferon-associated programs were not uniformly reversed, revealing differential responsiveness of metabolic and inflammatory pathways to HNF4α restoration. Together, these findings identify age-associated impairment of HNF4α activity as a functional contributor to liver aging, linking dysregulation of hepatocyte identity, metabolic homeostasis, and inflammatory control to age-associated hepatic dysfunction. Importantly, the selective reversibility of metabolic defects following HNF4α restoration establishes HNF4α as a promising strategy for preserving hepatocyte homeostasis and reversing age-associated hepatic metabolic dysfunction.
- Open Access
Disruption of the ARID1A-containing SWI/SNF complex reprograms tumor-associated macrophages and enhances immunotherapy response
Tumor-associated macrophages (TAMs) contribute to tumor immune evasion and therapeutic resistance. However, the epigenetic and transcriptional regulators that control TAM function remain largely unidentified. Here we investigated the role of the SWI/SNF chromatin remodeling complex in TAMs and whether disruption of SWI/SNF function in TAMs could improve immunotherapy. Pharmacologic inhibition of SWI/SNF ATPase activity improved the efficacy of checkpoint blockade immunotherapy, slowing tumor growth and reprogramming transcription broadly in tumor cells, tumor-infiltrating lymphocytes, and TAMs. To define the role of SWI/SNF in TAMs specifically, we genetically deleted the SWI/SNF subunit Arid1a in myeloid cells and found this was sufficient to suppress tumor progression and enhance checkpoint blockade response. Epigenomic and single cell analyses indicated that SWI/SNF inhibition and ARID1A deletion in TAMs reduced accessibility at enhancers of genes associated with poor prognosis, such as Spp1, and increased accessibility at promoters of interferon-stimulated genes (ISGs). CD86 was elevated on ARID1A-deficient TAMs and the enhanced immunotherapy response required CD86 costimulation and CD8+ T cells. These findings establish ARID1A-dependent chromatin remodeling as a determinant of TAM gene expression programs and show that disruption of myeloid SWI/SNF function improves checkpoint blockade immunotherapy via TAM reprogramming.
Open AccessDisruption of the ARID1A-containing SWI/SNF complex reprograms tumor-associated macrophages and enhances immunotherapy response
Tumor-associated macrophages (TAMs) contribute to tumor immune evasion and therapeutic resistance. However, the epigenetic and transcriptional regulators that control TAM function remain largely unidentified. Here we investigated the role of the SWI/SNF chromatin remodeling complex in TAMs and whether disruption of SWI/SNF function in TAMs could improve immunotherapy. Pharmacologic inhibition of SWI/SNF ATPase activity improved the efficacy of checkpoint blockade immunotherapy, slowing tumor growth and reprogramming transcription broadly in tumor cells, tumor-infiltrating lymphocytes, and TAMs. To define the role of SWI/SNF in TAMs specifically, we genetically deleted the SWI/SNF subunit Arid1a in myeloid cells and found this was sufficient to suppress tumor progression and enhance checkpoint blockade response. Epigenomic and single cell analyses indicated that SWI/SNF inhibition and ARID1A deletion in TAMs reduced accessibility at enhancers of genes associated with poor prognosis, such as Spp1, and increased accessibility at promoters of interferon-stimulated genes (ISGs). CD86 was elevated on ARID1A-deficient TAMs and the enhanced immunotherapy response required CD86 costimulation and CD8+ T cells. These findings establish ARID1A-dependent chromatin remodeling as a determinant of TAM gene expression programs and show that disruption of myeloid SWI/SNF function improves checkpoint blockade immunotherapy via TAM reprogramming.
- Open Access
- 1 January 2025
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 328 (1) , F15-F28
Western diet exacerbates a murine model of Balkan nephropathy
This study shows that a Western diet (WD) aggravates a murine model of Balkan nephropathy induced by the application of the organic anion and nephrotoxin aristolochic acid (AA). Mechanistically, this may involve WD-induced kidney organic anion secretion, which can facilitate the AA uptake into proximal tubular cells and thereby contribute to the injury. Kidney proteomics identified further changes induced by feeding a WD that could have increased the sensitivity of the kidney to stress and injury.
- 1 January 2025
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 328 (1) , F15-F28
Open AccessWestern diet exacerbates a murine model of Balkan nephropathy
This study shows that a Western diet (WD) aggravates a murine model of Balkan nephropathy induced by the application of the organic anion and nephrotoxin aristolochic acid (AA). Mechanistically, this may involve WD-induced kidney organic anion secretion, which can facilitate the AA uptake into proximal tubular cells and thereby contribute to the injury. Kidney proteomics identified further changes induced by feeding a WD that could have increased the sensitivity of the kidney to stress and injury.
- Open Access
Chronic pancreatitis patient-derived organoids reveal new paths to precision therapeutics
Summary: Chronic pancreatitis (CP) affects ∼3 million people worldwide, yet altering the course of disease is challenging. We developed a patient-derived organoid (PDO) platform to investigate the molecular pathogenesis of this disease and identify therapeutic strategies. We generated 36 PDOs from patients with idiopathic, hereditary, and alcohol-related CP with high genetic concordance. PDOs retained inflammation-associated transcriptional and proteomic features. Transcriptomic profiling revealed three molecular subtypes of CP independent of etiology. We discovered widespread dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) in half of the CP PDOs, including those with wildtype CFTR. Clinically available CFTR modulators stabilized mutant or wildtype CFTR, restored CFTR function, and decreased mitogenic and inflammatory signaling. This work provides the first comprehensive PDO platform for modeling CP. We demonstrate the utility of this platform for precision therapeutic investigations. Our findings reveal CFTR modulators as a broadly applicable and effective therapeutic strategy.
Open AccessChronic pancreatitis patient-derived organoids reveal new paths to precision therapeutics
Summary: Chronic pancreatitis (CP) affects ∼3 million people worldwide, yet altering the course of disease is challenging. We developed a patient-derived organoid (PDO) platform to investigate the molecular pathogenesis of this disease and identify therapeutic strategies. We generated 36 PDOs from patients with idiopathic, hereditary, and alcohol-related CP with high genetic concordance. PDOs retained inflammation-associated transcriptional and proteomic features. Transcriptomic profiling revealed three molecular subtypes of CP independent of etiology. We discovered widespread dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) in half of the CP PDOs, including those with wildtype CFTR. Clinically available CFTR modulators stabilized mutant or wildtype CFTR, restored CFTR function, and decreased mitogenic and inflammatory signaling. This work provides the first comprehensive PDO platform for modeling CP. We demonstrate the utility of this platform for precision therapeutic investigations. Our findings reveal CFTR modulators as a broadly applicable and effective therapeutic strategy.